US 10493077
Fused imidazo-piperidine JAK inhibitor compound
granted A61KA61K31/5377A61K9/0019
Quick answer
US patent 10493077 (Fused imidazo-piperidine JAK inhibitor compound) held by Theravance Biopharma R&D IP, LLC expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/5377, A61K9/0019, A61K9/0048, A61K9/10